FDA Approves Merck’s ENFLONSIA™ to Prevent RSV in Infants
The Pharma Data
JUNE 9, 2025
This new monoclonal antibody therapy is designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in neonates and infants born during or entering their first RSV season. RSV disease is the leading cause of infant hospitalization in the U.S. Key results from the CLEVER trial include: A 60.5%
Let's personalize your content